Bank of New York Mellon Corp Has $1.54 Million Position in BioTime, Inc. (BTX)

Bank of New York Mellon Corp boosted its stake in shares of BioTime, Inc. (NYSEMKT:BTX) by 17.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 445,031 shares of the biotechnology company’s stock after buying an additional 66,195 shares during the period. Bank of New York Mellon Corp owned about 0.43% of BioTime worth $1,535,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of BTX. Hikari Power Ltd bought a new position in shares of BioTime during the first quarter valued at about $122,000. Nationwide Fund Advisors boosted its stake in shares of BioTime by 2.2% in the first quarter. Nationwide Fund Advisors now owns 44,578 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 939 shares in the last quarter. Berson & Corrado Investment Advisors LLC boosted its stake in shares of BioTime by 83.1% in the first quarter. Berson & Corrado Investment Advisors LLC now owns 61,875 shares of the biotechnology company’s stock valued at $213,000 after buying an additional 28,075 shares in the last quarter. Two Sigma Investments LP boosted its stake in shares of BioTime by 86.9% in the fourth quarter. Two Sigma Investments LP now owns 66,135 shares of the biotechnology company’s stock valued at $239,000 after buying an additional 30,753 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in shares of BioTime by 306.7% in the first quarter. Russell Investments Group Ltd. now owns 96,303 shares of the biotechnology company’s stock valued at $333,000 after buying an additional 72,624 shares in the last quarter.

Shares of BioTime, Inc. (NYSEMKT:BTX) traded up 1.20% during trading on Friday, hitting $2.54. The company had a trading volume of 252,459 shares. The stock has a market capitalization of $294.14 million, a price-to-earnings ratio of 4.27 and a beta of 1.37. BioTime, Inc. has a 12-month low of $2.50 and a 12-month high of $4.01. The stock has a 50-day moving average of $2.87 and a 200 day moving average of $3.11.

ILLEGAL ACTIVITY WARNING: This article was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.com-unik.info/2017/08/19/bank-of-new-york-mellon-corp-buys-66195-shares-of-biotime-inc-btx-updated-updated-updated.html.

A number of analysts have recently commented on BTX shares. Zacks Investment Research cut BioTime from a “buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $6.50 price target (up from $6.00) on shares of BioTime in a research note on Monday, June 19th. ValuEngine raised BioTime from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd. Finally, BidaskClub cut BioTime from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $5.33.

In other news, Director Broadwood Partners, L.P. acquired 150,000 shares of the firm’s stock in a transaction dated Monday, July 31st. The stock was purchased at an average price of $2.80 per share, for a total transaction of $420,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

BioTime Company Profile

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Institutional Ownership by Quarter for BioTime (NYSEMKT:BTX)

What are top analysts saying about BioTime Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioTime Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit